Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes

Leukemia Research

Volumn 33, Issue 12, 2009, Pages 1594-1598

  Wang, Rong ^a   Gross, Cary P ^a   Halene, Stephanie ^a   Ma, Xiaomei ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Comorbid conditions; Myelodysplastic syndromes; Prognostic factors; Survival

Indexed keywords

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; DEATH; DEMENTIA; DIABETES MELLITUS; FEMALE; HEART INFARCTION; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PARALYSIS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; ULCER;

AGED; AGED, 80 AND OVER; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; PROPORTIONAL HAZARDS MODELS;

EID: 70249122797     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.02.005     Document Type: Article

References (38)

1. Ma X., Does M., Raza A., and Mayne S.T. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109 (2007) 1536-1542
2. Bennett J, editor. The myelodysplastic syndromes: pathobiology and clinical management. In: Cheson B, editor. Basic and clinical oncology, vol. 27. New York: Marcel Dekker; 2002.
3. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
4. Hoffman C., Rice D., and Sung H.Y. Persons with chronic conditions. Their prevalence and costs. JAMA 276 (1996) 1473-1479
5. Extermann M., Overcash J., Lyman G.H., Parr J., and Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16 (1998) 1582-1587
6. Piccirillo J.F., and Feinstein A.R. Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer 77 (1996) 834-842
7. Tammemagi C.M., Nerenz D., Neslund-Dudas C., Feldkamp C., and Nathanson D. Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 294 (2005) 1765-1772
8. Sanabria A., Carvalho A.L., Vartanian J.G., Magrin J., Ikeda M.K., and Kowalski L.P. Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol (2007)
9. Jacot W., Colinet B., Bertrand D., et al. Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients. Ann Oncol 19 (2008) 1458-1464
10. Estey E., and Dohner H. Acute myeloid leukaemia. Lancet 368 (2006) 1894-1907
11. Boehm A., Sperr W.R., Leitner G., et al. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation. Eur J Clin Invest 38 (2008) 945-952
12. Pelz D., Nachtkamp K., Kündgen A., Strupp C., Haas R., and Germing U. C015 Influence of comorbidity factors on the prognosis of patients with myelodysplastic syndromes (MDS). Leuk Res 31 (2007) S30-S31
13. Della Porta M.G., Kuendgen A., Malcovati L., et al. Myelodysplastic syndrome (MDS)-specific comorbidity index for predicting the impact of extra-hematological comorbidities on survival of patients with MDS. ASH Annu Meet Abstr 112 (2008) 2677
14. Della Porta M.G., Malcovati L., Travaglino E., et al. A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes. ASH Annu Meet Abstr 110 (2007) 2453
15. In: Fritz A. (Ed). International classification of diseases for oncology. 3rd ed. (2000), World Health Organization
16. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
17. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17 (1999) 3835-3849
18. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
19. Warren J.L., Klabunde C.N., Schrag D., Bach P.B., and Riley G.F. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40 (2002) IV-3-IV-18
20. Sharma G., Freeman J., Zhang D., and Goodwin J.S. Trends in end-of-life ICU use among older adults with advanced lung cancer. Chest 133 (2008) 72-78
21. Wong Y.N., Mitra N., Hudes G., et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 296 (2006) 2683-2693
22. Keating N.L., Landrum M.B., Meara E., Ganz P.A., and Guadagnoli E. Do increases in the market share of managed care influence quality of cancer care in the fee-for-service sector?. J Natl Cancer Inst 97 (2005) 257-264
23. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373-383
24. Romano P.S., Roos L.L., and Jollis J.G. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 46 (1993) 1075-1079 discussion 1081-1090
25. Bach P.B., Guadagnoli E., Schrag D., Schussler N., and Warren J.L. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care 40 (2002) IV-19-IV-25
26. Wolff J.L., Starfield B., and Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med 162 (2002) 2269-2276
27. Anisimov V.N. Carcinogenesis and aging 20 years after: escaping horizon. Mech Ageing Dev (2008)
28. Extermann M. Interaction between comorbidity and cancer. Cancer Control 14 (2007) 13-22
29. Read W.L., Tierney R.M., Page N.C., et al. Differential prognostic impact of comorbidity. J Clin Oncol 22 (2004) 3099-3103
30. Diaconescu R., Flowers C.R., Storer B., et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 104 (2004) 1550-1558
31. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 104 (2004) 961-968
32. Sorror M.L., Maris M.B., Sandmaier B.M., et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 3819-3829
33. Mielcarek M., Burroughs L., Leisenring W., et al. Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. Br J Haematol 129 (2005) 381-391
34. Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 23 (2005) 1993-2003
35. Maris M.B., Sandmaier B.M., Storer B.E., et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104 (2004) 3535-3542
36. Sorror M.L., Sandmaier B.M., Storer B.E., et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 25 (2007) 4246-4254
37. Germing U., Gattermann N., Strupp C., Aivado M., and Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 24 (2000) 983-992
38. Rollison D.E., Howlader N., Smith M.T., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 112 (2008) 45-52